Reeve Benaron is one of the world’s leading experts on stroke and neuroplasticity.

A neuroscientist, he has spent the last 20 years studying and applying neuroplasticity for patients in hospitals, consulting rooms, and private practice. He is a Professor of Neurology and Neuroscience at the University of Miami Miller School of Medicine and an Instructor in Psychiatry at Harvard Medical School.


He is also a founder/director at a non-profit organization called Stroke Recovery Institute, which offers unrestricted stroke rehabilitation consultations to all patients who have undergone one or more strokes within the last 180 days (or no less than 60 days). Healthcare and business expert Reeve Benaron’s knowledge spans various topics such as stroke, Alzheimer’s, brain mapping, depressive disorders, and brain tumor removal surgery. 


He has published over 100 scientific articles in highly regarded journals in neurology and psychiatry. He is a consultant to the International Dyslexia Association and a speaker for the New England Brain Bank on Stroke. Reeve Benaron also teaches aphasia classes to students of neurology and psychiatry in the United States, Latin America, and Europe. 


In his 20 years practicing medicine, he has worked with worldwide known healthcare expert Dr. Oliver Sacks and Dr. Eric Kandel from Columbia University (both awardees of the Nobel Prize) and many other luminaries of today’s medical research field. Reeve Benaron notes that this prize goes for scientists such as Dr. Stanley Prusiner (winner of the Nobel Prize for Medicine).

Benaron had his first stroke in 1999, which left him with aphasia. Several years later, he suffered another stroke that left him unable to speak or write. However, Dr. Benaron has learned to communicate through facial gestures, body language, and writing. He has since become a crusader for stroke prevention and rehabilitation to solve the problems of this devastating disease which affects approximately 10 million people worldwide annually. Reeve Benaron achieved a remarkable milestone in 2012 by launching the Covid-19 rapid antigen test.